Navigation Links
Defense Witness In Second Hepatitis C Trial In Nevada, Dr. Arthur Reingold, Testimony on Plausible Cause for Contamination Impeached
Date:10/1/2011

LAS VEGAS, Oct. 1, 2011 /PRNewswire/ -- This information is being released by SCM:

Dr. Arthur Reingold, witness for the defense in the second hepatitis C trial in Nevada, was called to the stand today offering expert testimony as an epidemiologist. During questioning by the defense, Dr. Reingold testified transference of the deadly virus hepatitis C could have occurred from a lack of hand washing, ungloved hands, bite blocks, biopsy equipment, gowns and aprons, and that cross contamination of bacteria may have occurred on a daily basis. 

(Photo:  http://photos.prnewswire.com/prnh/20111001/LA78785)

When cross examined by lead trial attorney for the plaintiffs, Robert Eglet, Dr. Reingold responded to questions about his testimony concerning transmission of hepatitis C at the Endoscopy Center of Southern Nevada.

"You can not state with certainty or to any reasonable degree of medical probability or have any evidence that the GI techs or any specific person was not wearing gloves, or that ungloved hands were the cause of transmission of the hepatitis C virus, or that the CRNAs were not washing their hands or wearing gowns or aprons that may have served as the source of the transmission of hepatitis C to Anne Arnold?" said Eglet. "No," stated Reingold. So you are not saying that hepatitis C on an apron somehow found its way into the bloodstream of Anne Arnold, Correct?" said Eglet. "Yes," stated Reingold.

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. 50mL infusion vials of Propofol are meant for long tern sedation of patients, not short outpatient procedures like colonoscopies. Arnold was later diagnosed as having contracted hepatitis C. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor. 

This is the second trial following the largest notification by the Clark County Health Department that 50,000 residents of Nevada may be infected. In the complaint filed in Clark County District Court by Mainor Eglet Law Firm attorneys Robert Eglet, Robert Adams and Artemus Ham on behalf of plaintiffs Anne Arnold and spouse James Arnold -- the defendants Teva Parenteral Medicines, Inc.; SICOR Inc. and Baxter Healthcare Corporation -- are each responsible in some manner for causing injury and damages to the plaintiffs. 


'/>"/>
SOURCE SCM
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
2. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
3. Lehigh University leads Department of Defense MURI grant for atomic-scale interphase research
4. Winners of inaugural defense fellowships to further research at NTU
5. Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure
6. Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defenses Net Zero Energy Initiative
7. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
8. TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs
9. NJIT physicist sees terahertz imaging as ultimate defense against terrorism
10. Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
11. UCLA gets $5.5 million from Defense agency to create new rotating microscale motors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... THOUSAND OAKS, Calif. , Dec. 2, 2016 ... AGN ) today announced the submission of a ... for ABP 215, a biosimilar candidate to Avastin ® ... biosimilar application submitted to the EMA. "The ... milestone as Amgen seeks to expand our oncology portfolio," said ...
(Date:12/2/2016)... -- Research and Markets has announced the addition ... Companies" to their offering. ... , , ... industries is anticipated. Nanotechnology will be applied at all stages ... diagnostic applications in clinical trials. Many of the assays based ...
(Date:12/2/2016)... , ... December 01, 2016 ... ... will share findings demonstrating the value of DNA microarray comparative genomic hybridization ... year’s San Antonio Breast Cancer Symposium. Using molecular test results from tumors ...
(Date:12/2/2016)... ... 01, 2016 , ... PhUSE will build on the huge ... Single Day Events (SDE) to organize a multiple-day US conference. The first annual ... of the pharmaceutical and life sciences industry will cover industry standards, data science, ...
Breaking Biology Technology:
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):